ARCA biopharma, Inc. (NASDAQ:ABIO) Files An 8-K Shareholder Director Nominations

ARCA biopharma, Inc. (NASDAQ:ABIO) Files An 8-K Shareholder Director Nominations
Item 5.08. Shareholder Director Nominations.

Story continues below

On October 10, 2019, the board of directors (the “Board”) of ARCA biopharma, Inc., a Delaware corporation (the “Company”), approved December 10, 2019 as the date of the Company’s 2019 Annual Meeting of Stockholders (the “Annual Meeting”). The Board also approved October 14, 2019 as the record date for stockholders entitled to notice of and to vote at the Annual Meeting.

Due to the fact that the Annual Meeting will be held more than 30 calendar days from the date of the Company’s 2018 Annual Meeting of Stockholders, the due dates for the provision of any qualified stockholder proposal or qualified stockholder nominations under the rules of the Securities and Exchange Commission (the “SEC”) and the bylaws of the Company listed in the Company’s 2018 Proxy Statement on Schedule 14A as filed with the SEC on April 23, 2018 are no longer applicable. Such nominations or proposals, including any notice on Schedule 14N, are now due to the Company no later than October 18, 2019. The Company currently intends to make its proxy materials available beginning on or about October 28, 2019.

About ARCA biopharma, Inc. (NASDAQ:ABIO)

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.

An ad to help with our costs